Trials / Completed
CompletedNCT02121990
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
A Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety of the drug olaparib at different dose levels. It will be given with the standard initial chemotherapy for cancer as well as a drug called bevacizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Paclitaxel, | |
| DRUG | Bevacizumab | |
| DRUG | Cisplatin | |
| DRUG | Olaparib |
Timeline
- Start date
- 2014-04-21
- Primary completion
- 2020-08-19
- Completion
- 2020-08-19
- First posted
- 2014-04-24
- Last updated
- 2020-08-21
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02121990. Inclusion in this directory is not an endorsement.